Cai N, Hu P
Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
Zhonghua Gan Zang Bing Za Zhi. 2024 Apr 20;32(4):295-299. doi: 10.3760/cma.j.cn501113-20240325-00156.
The ideal goal of hepatitis B treatment is to achieve a functional cure, and the persistent cccDNA in the liver is a barrier to functional cure. Currently, antiviral drugs represented by pegylated interferon-α and nucleos (t) ide analogues cannot eliminate cccDNA, which is difficult to achieve functional cure. With the deepening of the exploration of various mechanisms and drug targets, significant progress has been made in the research and development of several novel drugs targeting the hepatitis B virus's life cycle and immune system, offering hope for a functional cure. This article presents an overview of the new progress in clinical research on antiviral therapy for chronic hepatitis B based on the literature published in recent years and international conference materials.
乙型肝炎治疗的理想目标是实现功能性治愈，而肝脏中持续存在的cccDNA是实现功能性治愈的障碍。目前，以聚乙二醇化干扰素-α和核苷（酸）类似物为代表的抗病毒药物无法消除cccDNA，难以实现功能性治愈。随着对各种机制和药物靶点探索的深入，针对乙肝病毒生命周期和免疫系统的几种新型药物的研发取得了显著进展，为功能性治愈带来了希望。本文基于近年来发表的文献和国际会议资料，对慢性乙型肝炎抗病毒治疗的临床研究新进展进行综述。
